{"id":411658,"date":"2026-01-14T05:47:06","date_gmt":"2026-01-14T05:47:06","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/411658\/"},"modified":"2026-01-14T05:47:06","modified_gmt":"2026-01-14T05:47:06","slug":"the-next-3-years-could-be-huge-for-this-asx-healthcare-stock-heres-why","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/411658\/","title":{"rendered":"The next 3 years could be huge for this ASX healthcare stock. Here\u2019s why"},"content":{"rendered":"<p><img width=\"1200\" height=\"675\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/01\/health-1200x675.jpg\" class=\"attachment-full size-full wp-post-image\" alt=\"A male doctor and a woman in scrubs in the foreground smile.\" decoding=\"async\" fetchpriority=\"high\"  \/><\/p>\n<p>Image source: Getty Images<\/p>\n<p>An ASX healthcare stock is back in focus today after a fresh update lifted confidence in its long-term outlook.<\/p>\n<p>The\u00a0Neuren Pharmaceuticals Ltd\u00a0(<a class=\"tickerized-link\" href=\"https:\/\/www.fool.com.au\/tickers\/asx-neu\/\" rel=\"nofollow noopener\" target=\"_blank\">ASX: NEU<\/a>) share price is up 7.77% to $20.80.<\/p>\n<p>Over the past year, the stock has climbed around 70%, making it one of the strongest ASX performers in the healthcare sector.<\/p>\n<p>Let&#8217;s take a closer look at what the company announced to the market.<\/p>\n<p> What&#8217;s behind today&#8217;s update <\/p>\n<p>Today&#8217;s\u00a0<a href=\"https:\/\/www.fool.com.au\/tickers\/asx-neu\/announcements\/2026-01-14\/2a1648202\/daybue-net-sales-projected-to-reach-approx-us700m-in-2028\/\" rel=\"nofollow noopener\" target=\"_blank\">update<\/a>\u00a0focused on the company&#8217;s main product, DAYBUE, which is used to treat Rett syndrome, a rare neurological condition.<\/p>\n<p>The company&#8217;s US partner now believes global sales could reach about US$700 million by 2028. That is a big increase from current levels and suggests demand for the treatment is continuing to grow.<\/p>\n<p>More than 2,000 patients in the US have now been treated with DAYBUE. Importantly, around 55% of patients are still using the drug after 12 months, which has helped support steady, repeat revenue over time.<\/p>\n<p>Further growth is anticipated from the introduction of a new powder version of the drug, a larger US sales team, and potential approvals in Europe and other markets.<\/p>\n<p>A key benefit for Neuren is that it earns milestone payments and royalties, while its partner handles most of the sales and marketing costs.<\/p>\n<p> Why investors are taking notice <\/p>\n<p>This update helps explain why investors continue to back the stock, even after its strong run.<\/p>\n<p>Neuren is now\u00a0<a href=\"https:\/\/www.fool.com.au\/definitions\/market-capitalisation\/\" rel=\"nofollow noopener\" target=\"_blank\">valued<\/a>\u00a0at about $2.5 billion, despite having just one approved product. However, that product is already generating solid income and still has plenty of room to grow. <\/p>\n<p>The company also has another drug in late-stage development, which could add a second source of revenue in the future.<\/p>\n<p> What the chart is telling us <\/p>\n<p>Looking at the technical side of things, the share price remains in a healthy uptrend.<\/p>\n<p>The stock has been moving sideways between $18.50 and $21 for several months, with buyers stepping in around the $18.50 to $19 level. The price is still sitting above key trend lines. <\/p>\n<p>The\u00a0<a href=\"https:\/\/www.fool.com.au\/definitions\/rsi-indicator\/\" rel=\"nofollow noopener\" target=\"_blank\">relative strength index (RSI)<\/a>\u00a0is sitting near neutral levels, suggesting the stock is not overbought, despite the strong 12-month run. That leaves room for further upside if positive news continues.<\/p>\n<p> Foolish bottom line <\/p>\n<p>Today&#8217;s announcement supports the long-term growth outlook for Neuren.<\/p>\n<p>There is clear momentum in sales and patient numbers, with more growth opportunities ahead. While expectations are high, the business continues to make steady progress. <\/p>\n","protected":false},"excerpt":{"rendered":"Image source: Getty Images An ASX healthcare stock is back in focus today after a fresh update lifted&hellip;\n","protected":false},"author":2,"featured_media":411659,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,63,137,500],"class_list":["post-411658","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-au","tag-australia","tag-health","tag-healthcare"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/411658","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=411658"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/411658\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/411659"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=411658"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=411658"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=411658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}